Table 1 General characterization of study cohort
From: Incidence of acute kidney injury among COVID-19 patients in Egypt
| Â | No AKI patients (n=560) | AKI patients (n=91) | OR (95% CI) | P. value |
|---|---|---|---|---|
Variables | Â | Â | Â | Â |
 Age | 55 (43–67) | 57.5 (51–64) | 6.3776 (4.1419–9.8202) | < 0.001 |
 Male | 320 (57.2%) | 57 (62.6%) | 1.0962 (0.7660–1.5687) | 0.6157 |
 BMI | 29±1.5 | 30±2.6 | 6.3660 (3.6494–11.1050) | < 0.001 |
Comorbidities | ||||
 Diabetes | 264 (47.14%) | 33 (36.2%) | 0.7692 (0.5032–1.1758) | 0.2255 |
 Hypertension | 380 (67.8%) | 53 (58%) | 0.8583 (0.5971–1.2338) | 0.4092 |
 Cardiac disease | 74.0 (13.2%) | 11 (12%) | 0.9148 (0.4676–1.7894) | 0.7947 |
 Asthma | 31.0 (5.53%) | 2 (2.0%) | 0.3970 (0.0934–1.6875) | 0.2108 |
 Chronic liver disease | 108 (19.3%) | 6 (6.5%) | 0.3419 (0.1459–0.8010) | 0.0135 |
 Cancer | 28.0 (5.0%) | 11 (12%) | 2.4176 (1.1630–5.0256) | 0.0181 |
Presentations | ||||
 Fever | 304 (54.3%) | 78 (85.7%) | 1.5789 (1.1316–2.2031) | 0.0072 |
 Cough | 512 (91.4%) | 66 (72.5% | 0.7933 (0.5653–1.1132) | 0.1803 |
 Dyspnea | 359 (64.1%) | 77 (84.6%) | 1.3199 (0.9478–1.8381) | 0.1004 |
 Sore throat | 349 (62.3%) | 17 (18.7%) | 0.2998 (0.1756–0.5117) | < 0.001 |
 Diarrhea | 86.0 (15.4%) | 17 (18.7%) | 1.2165 (0.6911–2.1412) | 0.4970 |
 Fatigue | 251 (45.0%) | 37 (40.6%) | 0.9071 (0.6019–1.3671) | 0.6414 |
 Abdominal pain | 39.0 (6.9%) | 8 (8.8%) | 1.2623 (0.5716–2.7879) | 0.5644 |
 Myalgia | 143 (25.5%) | 16 (17.5%) | 0.6885 (0.3924–1.2080) | 0.1932 |
Laboratory results | ||||
 HB%, g/dL | 13.55 (12.3–14.8) | 11.6 (10.0–13.2) | 5.2747 (2.3648–11.7656) | < 0.001 |
 WBCs, ×103/μ L | 7.7 (5.9–9.5) | 10.0 (5.7–14.5) | 7.6923 (2.9579–20.0045) | < 0.001 |
 PLT, ×103/μ L | 222.5 (160–285) | 173.4 (107–239.8) | 4.8017 (3.5668–6.4640) | < 0.001 |
 CRP, mg/dL | 306 (64–600) | 920.5 (566–1275) | 18.5219 (14.3312–23.9380) | < 0.001 |
 B. urea, mg/dL | 32.5 (20–45) | 135 (70–200) | 25.1748 (16.2072–39.1044) | < 0.001 |
 S. creatinine, mg/dL | 0.9 (0.6–1.2) | 7.5 (1.3–13.7) | 43.0769 (5.2382–354.2467) | < 0.001 |
 D-dimer, mg/mL | 561.5 (233–890) | 1435.75 (891.5–1980) | 15.7241 (12.3437–20.0301) | < 0.001 |
Type of isolation | ||||
 Home | 120 (18.4%) | 13 (14.3%) | 0.6667 (0.3609–1.2315) | 0.1953 |
 Hospital | 327 (50.3%) | 49 (53.8%) | 0.9221 (0.6350–1.3392) | 0.6702 |
 ICU | 204 (31.3%) | 29 (31.9%) | 0.8748 (0.5591–1.3687) | 0.5581 |
Outcomes | ||||
 Cure | 533 (95.2%) | 77 (84.6%) | 0.8890 (0.6418–1.2315) | 0.4792 |
 Death | 27 (4.8%) | 14 (15.4%) | 3.1909 (1.6126–6.3140) | < 0.001 |